liver transplant is the treatment of choice Nonsurgical treatments (PEI, RFA, and TACE) are employed to minimize drop-out from the transplant waiting list, which nevertheless occurs in 20% of ...

Hepatic resection and transplantation remain the standard curative therapies for hepatocellular carcinoma ... liver disease are best served by transplant evaluation; however, the best treatment ...

I was approved for a transplant, and just two days later ... Two months later, I was diagnosed with hepatocellular carcinoma, a type of liver cancer that's common in people with liver failure.

Patient (pt) characteristics, treatment patterns, and outcomes in unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) systemic therapy in the United States (US). Patterns of ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

A new model has projected a substantial rise in the burden of metabolic dysfunction-associated steatotic liver disease in the ...

Rates and risk factors for recurrence of hepatocellular carcinoma after initial complete remission in response to transcatheter arterial chemoembolization: A systematic review and meta-analysis. This ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.